Tags: Cancer | lung | cancer | drug | treatment | genetics

FDA Approves Drug for Rare Lung Cancer

FDA Approves Drug for Rare Lung Cancer
(Copyright DPC)

Tuesday, 15 March 2016 01:40 PM

A anti-cancer drug already used for lung cancer has won expanded approval from the U.S. Food and Drug Administration to treat another rare form of the disease.

The drug Xalkori (crizotinib) is already used to treat some forms of lung cancer, and now the agency also has expanded it for use in tumors that test positive for a genetic mutation known as ROS-1 that is found in non small cell lung cancer (NSCLC), which is the most common form of the often-deadly disease, the FDA said. 

"Lung cancer is difficult to treat, in part because patients have different mutations, some of which are rare. The expanded use of Xalkori will provide a valuable treatment option for patients with the rare and difficult-to-treat ROS-1 gene mutation,” says Dr. Richard Pazdur, director of the agency’s Office of Hematology and Oncology Products division.

By blocking the activity of the ROS-1 protein in tumors that have ROS-1 gene alterations, crizotinib may prevent NSCLC from growing and spreading, the FDA says.

The FDA evaluated the drug in 50 patients and found that 66 percent of them experienced complete or partial shrinkage of their tumors, an effect that lasted an average of 18.3 months, the FDA said.

These types of gene alterations are present in roughly 1 percent of patients with NSCLC.


© 2019 NewsmaxHealth. All rights reserved.

   
1Like our page
2Share
Health-News
Doctors treating a very rare form of lung cancer now have another drug in their arsenal after the U.S. Food and Drug Administration's decision to expand the use of an anti-cancer medication.
lung, cancer, drug, treatment, genetics
216
2016-40-15
Tuesday, 15 March 2016 01:40 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved